Contrast Media Market Size – By Component (Iodinated, Gadolinium, Microbubble, Barium), Form (Liquid, Powder), Modality, Route of Administration (Intravascular, Oral, Rectal), Application (Radiology, Cardiology), Indication, End User & Forecast, 2024 – 20

Report Content Chapter 1 Methodology & Scope 1.1 Market scope & definitions 1.2 Research design 1.2.1 Research approach 1.2.2 Data collection methods 1.3 Base estimates & calculations 1.3.1 Base year calculation 1.3.2 Key trends for market estimation 1.4 Forecast model 1.5 Primary research and validation 1.5.1 Primary sources 1.5.2 Data mining sources Chapter 2 Executive Summary 2.1 Industry 360-degree synopsis Chapter 3 Industry Insights 3.1 Industry ecosystem analysis 3.2 Industry impact forces 3.2.1 Growth drivers 3.2.1.1 Growing regulatory approvals of contrast media 3.2.1.2 Growth in radiological examinations 3.2.1.3 Surging incidence of chronic diseases 3.2.1.4 Increase in minimally invasive procedures 3.2.2 Industry pitfalls & challenges 3.2.2.1 Presence of stringent regulations and frequent product recalls 3.2.2.2 Allergic reactions and side-effects associated with contrast media 3.3 Growth potential analysis 3.4 Regulatory landscape 3.5 Porter's analysis 3.6 PESTEL analysis Chapter 4 Competitive Landscape, 2023 4.1 Introduction 4.2 Company market share analysis 4.3 Company matrix analysis 4.4 Competitive analysis of major market players 4.5 Competitive positioning matrix 4.6 Strategy dashboard Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn) 5.1 Key trends 5.2 Iodinated contrast media 5.3 Gadolinium-based contrast media 5.4 Microbubble contrast media 5.5 Barium-based contrast media Chapter 6 Market Estimates and Forecast, By Form, 2021 - 2032 ($ Mn) 6.1 Key trends 6.2 Liquid 6.3 Powder 6.4 Other forms Chapter 7 Market Estimates and Forecast, By Modality, 2021 - 2032 ($ Mn) 7.1 Key trends 7.2 X-ray 7.3 Computed tomography (CT) 7.4 Magnetic resonance imaging (MRI) 7.5 Ultrasound Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn) 8.1 Key trends 8.2 Intravascular route 8.3 Oral route 8.4 Rectal route 8.5 Other routes of administration Chapter 9 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn) 9.1 Key trends 9.2 Cardiovascular disease 9.3 Cancer 9.4 Gastrointestinal disorders 9.5 Musculoskeletal disroders 9.6 Neurological disroders 9.7 Nephrological disorders Chapter 10 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn) 10.1 Key trends 10.2 Radiology 10.3 Interventional radiology 10.4 Interventional cardiology Chapter 11 Market Estimates and Forecast, By End User, 2021 - 2032 ($ Mn) 11.1 Key trends 11.2 Hospitals, clinics, and ASCs 11.3 Diagnostic imaging center Chapter 12 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn) 12.1 Key trends 12.2 North America 12.2.1 U.S. 12.2.2 Canada 12.3 Europe 12.3.1 Germany 12.3.2 UK 12.3.3 France 12.3.4 Spain 12.3.5 Italy 12.3.6 Netherlands 12.3.7 Rest of Europe 12.4 Asia Pacific 12.4.1 China 12.4.2 Japan 12.4.3 India 12.4.4 Australia 12.4.5 South Korea 12.4.6 Rest of Asia Pacific 12.5 Latin America 12.5.1 Brazil 12.5.2 Mexico 12.5.3 Rest of Latin America 12.6 Middle East and Africa 12.6.1 South Africa 12.6.2 Saudi Arabia 12.6.3 UAE 12.6.4 Rest of Middle East and Africa Chapter 13 Company Profiles 13.1 Bayer AG 13.2 Bracco S.p.A. 13.3 GE HealthCare 13.4 Guerbet LLC 13.5 iMAX Diagnostic Imaging Limited 13.6 J.B. Chemicals & Pharmaceuticals Ltd. 13.7 Jodas Expoim Pvt. Ltd. 13.8 Lantheus Holdings, Inc. 13.9 Livealth Biopharma Pvt. Ltd. 13.10 nanoPET Pharma GmbH 13.11 Senochemia Pharmazeutika 13.12 Spago Nanomedical AB 13.13 TAEJOON Pharmaceutical Co., Ltd. 13.14 Trivitron Healthcare 13.15 Unijules Life Sciences Ltd.